ATAGI 2025 Annual Statement on Immunisation

Authors

  • Katrina Nicolopoulos National Centre for Immunisation Research and Surveillance, Children’s Hospital at Westmead, Sydney, New South Wales, Australia
  • Saskia van der Kooi National Centre for Immunisation Research and Surveillance, Children’s Hospital at Westmead, Sydney, New South Wales, Australia
  • Clayton Chiu National Centre for Immunisation Research and Surveillance, Children’s Hospital at Westmead, Sydney, New South Wales, Australia; Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney, New South Wales, Australia
  • Alexandra Hendry National Centre for Immunisation Research and Surveillance, Children’s Hospital at Westmead, Sydney, New South Wales, Australia
  • Kristine K Macartney National Centre for Immunisation Research and Surveillance, Children’s Hospital at Westmead, Sydney, New South Wales, Australia; Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney, New South Wales, Australia; Australian Technical Advisory Group on Immunisation, Department of Health, Australian Government, Canberra, Australian Capital Territory, Australia
  • A/Prof. Katherine Gibney Australian Technical Advisory Group on Immunisation, Department of Health, Australian Government, Canberra, Australian Capital Territory, Australia; Victorian Infectious Diseases Service, The Royal Melbourne Hospital, Victoria, Australia; Department of Infectious Diseases, University of Melbourne, Melbourne, Victoria, Australia
  • Prof. Katie Flanagan Australian Technical Advisory Group on Immunisation, Department of Health, Australian Government, Canberra, Australian Capital Territory, Australia; Centre for Infectious Diseases and Microbiology, Westmead Hospital, Sydney, New South Wales, Australia; School of Medicine, University of Tasmania, Hobart, Tasmania, Australia; School of Health and Biomedical Science, RMIT, Melbourne, Victoria, Australia
  • Michelle L Giles Australian Technical Advisory Group on Immunisation, Department of Health, Australian Government, Canberra, Australian Capital Territory, Australia; Department of Infectious Diseases, University of Melbourne, Melbourne, Victoria, Australia; Department of Obstetrics and Gynaecology, Monash University, Melbourne, Victoria, Australia
  • Nigel W Crawford Australian Technical Advisory Group on Immunisation, Department of Health, Australian Government, Canberra, Australian Capital Territory, Australia; Department of General Paediatrics, Royal Children’s Hospital, Melbourne, Victoria, Australia; Infection and Immunity, Murdoch Children’s Research Institute and University of Melbourne, Victoria, Australia

DOI:

https://doi.org/10.33321/cdi.2026.50.033

Keywords:

immunisation, vaccine preventable diseases, Australia

Abstract

The Australian Technical Advisory Group on Immunisation (ATAGI) 2025 Annual Statement on Immunisation is the fifth publication in this series. It highlights the key successes, trends and challenges in the use of vaccines and control of vaccine preventable diseases (VPDs) in Australia in 2024. It also signals ATAGI’s priority advice on actions to address key issues for 2025 and beyond.

Downloads

Download data is not yet available.

References

Australian Government Department of Health, Disability and Ageing. National Immunisation Program – Shingles vaccination – Program advice for health professionals. [Internet.] Canberra: Australian Government Department of Health, Disability and Ageing; 12 November 2024. Available from: https://www.health.gov.au/resources/publications/national-immunisation-program-shingles-vaccination-program-advice-for-health-professionals.

Australian Government Department of Health, Disability and Ageing. Health Technology Assessment Policy and Methods Review – Final report. Canberra: Australian Government Department of Health, Disability and Ageing; 10 September 2024. Available from: https://www.health.gov.au/resources/publications/health-technology-assessment-policy-and-methods-review-final-report.

Australian Government Department of the Prime Minister and Cabinet. COVID-19 Response Inquiry Report. Canberra, Australia: Australian Government Department of the Prime Minister and Cabinet; 29 October 2024. Available from: https://www.pmc.gov.au/resources/covid-19-response-inquiry-report.

Australian Government, Australian Centre for Disease Control (Australian CDC). National Immunisation Strategy for Australia 2025–2030. Canberra: Australian CDC; 12 May 2025. Available from: https://www.cdc.gov.au/resources/publications/national-immunisation-strategy-australia-2025-2030.

Australian Government Department of Health, Disability and Ageing. Broad expertise to lead health technology assessment reform. [Media release.] Canberra: Australian Government Department of Health, Disability and Ageing; 20 November 2024. Available from: https://www.health.gov.au/ministers/the-hon-mark-butler-mp/media/broad-expertise-to-lead-health-technology-assessment-reform.

Australian CDC. First mpox clade Ib confirmed in Australia. [Media release.] Canberra: Australian CDC; 16 May 2025. Available from: https://www.cdc.gov.au/newsroom/news-and-articles/first-mpox-clade-ib-confirmed-australia.

Africa Centres for Disease Control and Prevention (Africa CDC). Africa CDC Declares Mpox A Public Health Emergency of Continental Security, Mobilizing Resources Across the Continent. [News release.] Addis Ababa: Africa CDC; 13 August 2024. Available from: https://africacdc.org/news-item/africa-cdc-declares-mpox-a-public-health-emergency-of-continental-security-mobilizing-resources-across-the-continent/.

World Health Organization (WHO). WHO Director-General declares mpox outbreak a public health emergency of international concern. [News release.] Geneva: WHO; 14 August 2024. Available from: https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern.

Australian Government Department of Health, Disability and Ageing; Australian Immunisation Handbook. Mpox (previously known as monkeypox). [Webpage.] Canberra: Australian Government Department of Health, Disability and Ageing; 16 May 2024. Available from: https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/mpox-previously-known-as-monkeypox.

Australian Government Department of Health, Disability and Ageing. ATAGI Clinical Guidance on the use of vaccines for the prevention of Mpox. [Webpage.] Canberra: Australian Government Department of Health, Disability and Ageing; 20 December 2024. Available from: https://www.health.gov.au/resources/publications/atagi-clinical-guidance-on-the-use-of-vaccines-for-the-prevention-of-mpox.

Queensland State Government Department of Primary Industries (Queensland DPI). Outbreaks of avian influenza (bird flu). [Internet.] Brisbane: Queensland DPI; 17 February 2025. Available from: https://www.dpi.qld.gov.au/business-priorities/biosecurity/animal-biosecurity-welfare/animal-health-pests-diseases/reportable/avian-influenza-bird-flu.

Australian Government Department of Health, Disability and Ageing. ATAGI 107th meeting bulletin – 15 and 16 August 2024. [Webpage.] Canberra: Australian Government Department of Health, Disability and Ageing; 16 September 2024. Available from: https://www.health.gov.au/resources/publications/atagi-107th-meeting-bulletin-15-and-16-august-2024.

Australian CDC. Bird flu (avian influenza). [Webpage.] Canberra: Australian CDC; 19 January 2026. Available from: https://www.cdc.gov.au/topics/bird-flu.

Hassall J, Whitehead S, Welsh L, Donovan A, Bilgin G, Nguyen N et al. 2024 Annual Australian Respiratory Surveillance Report. Commun Dis Intell (2018). 2026;50. doi: https://doi.org/10.33321/cdi.2026.50.013.

Yin JK, Heywood AE, Georgousakis M, King C, Chiu C, Isaacs D et al. Systematic review and meta-analysis of indirect protection afforded by vaccinating children against seasonal influenza: implications for policy. Clin Infect Dis. 2017;65(5):719–28. doi: https://doi.org/10.1093/cid/cix420.

Government of Western Australia Department of Health (WA Health). Influenza immunisation. [Webpage.] Perth: WA Health; 5 September 2025. Available from: https://www.health.wa.gov.au/articles/f_i/influenza-immunisation-program.

Queensland Government Department of Health (Queensland Health). 2025 Free Flu Vaccination Program. [Webpage.] Brisbane: Queensland Health; 3 March 2025. Available from: https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/diseases-infection/immunisation/service-providers/2025-free-flu-vaccination-program.

Australian Government Department of Health, Disability and Ageing; Therapeutic Goods Administration (TGA). Arexvy: Australian Prescription Medicine Decision Summary. [Webpage.] Canberra: TGA; 22 January 2024. Available from: https://www.tga.gov.au/resources/auspmd/arexvy.

TGA. Abrysvo (RSV vaccine): Australian Prescription Medicine Decision Summary. [Webpage.] Canberra: TGA; 22 May 2024. Available from: https://www.tga.gov.au/resources/auspmd/abrysvo-rsv-vaccine.

TGA. mRESVIA respiratory syncytial virus F protein mRNA (nucleoside modified), 50 micrograms in 0.5 mL, suspension for injection, prefilled syringe. (411450). [Webpage.] Canberra: TGA; 28 March 2025. Available from: https://www.tga.gov.au/resources/artg/411450.

Australian Government Department of Health, Disability and Ageing; Australian Immunisation Handbook. Respiratory syncytial virus (RSV). [Webpage.] Canberra: Australian Government Department of Health, Disability and Ageing; 27 June 2024. Available from: https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/respiratory-syncytial-virus-rsv.

WA Health. 2025 WA Respiratory Syncytial Virus (RSV) Infant and Maternal Immunisation Program. [Webpage.] Perth: WA Health; 31 October 2025. Available from: https://www.health.wa.gov.au/articles/n_r/2025-wa-respiratory-syncytial-virus-rsv-infant-and-maternal-immunisation-program.

Queensland Health. Respiratory Syncytial Virus (RSV): Queensland Paediatric RSV Prevention Program. [Webpage.] Brisbane: Queensland Health; 16 January 2025. Available from: https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/diseases-infection/immunisation/schedule/paediatric-rsv-prevention-program#section__queensland-paediatric-rsv-prevention-program.

New South Wales Government Department of Health (NSW Health). NSW RSV Preventation Program - Frequently asked questions for health professional. [Webpage.] Sydney: NSW Health; 2 April 2025. Available from: https://www.health.nsw.gov.au/immunisation/pages/nirsevimab-professionals.aspx#who.

Tasmanian Government Department of Health (Tasmania Health). Communicable Disease Prevention Unit Bulletin: Respiratory Syncytial Virus (RSV) Immunisation Update. [Newsletter.] Hobart: Tasmania Health; 16 August 2024. Available from: https://www.health.tas.gov.au/newsletters/communicable-disease-prevention-unit-bulletin#:~:text=Respiratory%20Syncytial%20Virus%20(RSV)%20Immunisation%20Update.

Northern Territory Government Department of Health (NT Health). Immunisation program: Respiratory Syncytial Virus (RSV). [Webpage.] Darwin: NT Health; 2025. Available from: https://health.nt.gov.au/professionals/centre-for-disease-control/immunisation-program/respiratory-syncytial-virus-rsv.

Australian Government Department of Health, Disability and Ageing. World-leading approach to protect babies from RSV. Media release.] Canberra: Australian Government Department of Health, Disability and Ageing; 10 November 2024. Available from: https://www.health.gov.au/ministers/the-hon-mark-butler-mp/media/world-leading-approach-to-protect-babies-from-rsv.

TGA. COVID-19 vaccines regulatory status. [Webpage.] Canberra: TGA; 24 July 2025. Available from: https://www.tga.gov.au/products/medicines/prescription-medicines/application-and-market-authorisation/covid-19-vaccine-information-sponsors-industry/covid-19-vaccines-regulatory-status.

Australian Government Department of Health, Disability and Ageing. ATAGI statement on the administration of COVID-19 vaccines in 2024. [Webpage.] Canberra: Australian Government Department of Health, Disability and Ageing; 1 March 2024. Available from: https://www.health.gov.au/resources/publications/atagi-statement-on-the-administration-of-covid-19-vaccines-in-2024.

Hull B, Hendry A, McCartney K, Beard F. Annual Immunisation Coverage Report 2023. Commun Dis Intell (2018). 2026;50. doi: https://doi.org/10.33321/cdi.2026.50.001.

Australian Government Department of Health, Disability and Ageing. Changes to HPV vaccine dose schedule for young Australians. [Webpage.] Canberra: Australian Government Department of Health, Disability and Ageing; 6 February 2023. Available from: https://www.health.gov.au/news/changes-to-hpv-vaccine-dose-schedule-for-young-australians.

Australian Government Department of Health, Disability and Ageing. National Strategy for the Elimination of Cervical Cancer in Australia. [Webpage.] Canberra: Australian Government Department of Health, Disability and Ageing; 17 November 2023. Available from: https://www.health.gov.au/resources/publications/national-strategy-for-the-elimination-of-cervical-cancer-in-australia.

Australian Government Department of Health, Disability and Ageing. National Immunisation Program (NIP) Meningococcal ACWY changes from 1 July 2024. [Webpage.] Canberra: Australian Government Department of Health, Disability and Ageing; 1 July 2024. Available from: https://www.health.gov.au/news/national-immunisation-program-nip-meningococcal-acwy-changes-from-1-july-2024.

Australian Government Department of Health, Disability and Ageing. National Immunisation Program – Shingles vaccination – Program advice for health professionals. Canberra: Australian Government Department of Health, Disability and Ageing; 12 November 2024. Available from: https://www.health.gov.au/resources/publications/national-immunisation-program-shingles-vaccination-program-advice-for-health-professionals.

Pharmacy Programs Administrator (PPA). Program Rules: National Immunisation Program Vaccinations in Pharmacy (NIPVIP) Program. Australian Government Department of Health, Disability and Ageing, PPA; September 2025. Available from: https://www.ppaonline.com.au/wp-content/uploads/2023/11/NIPVIP-Program-Rules.pdf.

National Centre for Immunisation Research and Surveillance (NCIRS). Vaccination from community pharmacy – at a glance. Sydney: Sydney Children’s Hospitals Network, NCIRS; March 2025. Available from: https://ncirs.org.au/fact-sheets-faqs/vaccines-from-community-pharmacy.

Australian Government Department of Health, Disability and Ageing. COVID-19 Vaccine Claims Scheme. [Webpage.] Canberra: Australian Government Department of Health, Disability and Ageing; 8 October 2024. Available from: https://www.health.gov.au/our-work/covid-19-vaccine-claims-scheme#updates-to-the-scheme.

AusVaxSafety. Shingrix. [Webpage.] Sydney: Sydney Children’s Hospitals Network, NCIRS. Available from: https://ausvaxsafety.org.au/vaccine-safety-data/shingrix.

TGA. Shingrix vaccine and very rare risk of Guillain-Barré Syndrome. [Webpage.] Canberra: TGA; 29 October 2024. Available from: https://www.tga.gov.au/news/safety-updates/shingrix-vaccine-and-very-rare-risk-guillain-barre-syndrome.

AusVaxSafety. Arexvy RSV vaccine safety data – older adults. [Webpage.] Sydney: Sydney Children’s Hospitals Network, NCIRS. Available from: https://ausvaxsafety.org.au/rsv-vaccines/arexvy-rsv-vaccine-safety-data-older-adults.

Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451–64. doi: https://doi.org/10.1056/NEJMoa2216480.

AusVaxSafety. Nirsevimab. [Webpage.] Sydney: Sydney Children’s Hospitals Network, NCIRS. Available from: https://ausvaxsafety.org.au/vaccine-safety-data/nirsevimab.

Carcione D, Spencer P, Pettigrew G, Leeb A, Drake-Brockman C, Ford T et al. Active post-marketing safety surveillance of nirsevimab administered to children in Western Australia, April–July 2024. Pediatr Infect Dis J. 2025;44(5):e174–6. doi: https://doi.org/10.1097/INF.0000000000004715.

TGA. Addressing misinformation about excessive DNA in the mRNA vaccines. [Media release.] Canberra: TGA; 18 October 2024. Available from: https://www.tga.gov.au/news/media-releases/addressing-misinformation-about-excessive-dna-mrna-vaccines.

Australian Government Therapeutic Goods Administration. Summary report of residual DNA and endotoxin on COVID-19 mRNA vaccines conducted by TGA Laboratories. [Webpage.] Canberra: TGA; 7 November 2024. Available from: https://www.tga.gov.au/resources/publication/tga-laboratory-testing-reports/summary-report-residual-dna-and-endotoxin-covid-19-mrna-vaccines-conducted-tga-laboratories.

Aotearoa New Zealand Government Ministry of Health – Manatū Hauora (NZ Ministry of Health). National Immunisation Technical Advisory Group (NITAG). [Internet.] Wellington: NZ Ministry of Health; 27 June 2024. Available from: https://www.health.govt.nz/information-releases/national-immunisation-technical-advisory-group-nitag.

Australian Government Department of Health, Disability and Ageing. ATAGI strategic intent. [Webpage.] Canberra: Australian Government Department of Health, Disability and Ageing; 10 September 2020. Available from: https://www.health.gov.au/resources/publications/atagi-strategic-intent.

Dark and light blue shapes displaying the logo of Communicable Diseases Intelligence with a celebration graphic for Volume 50. The bottom of the cover features a lockup of the logo of the Australian Centre for Disease Control alongside the Commonwealth Coat of Arms.

Downloads

Published

26/05/26

How to Cite

Nicolopoulos, Katrina, Saskia van der Kooi, Clayton Chiu, Alexandra Hendry, Kristine Macartney, Katherine Gibney, Katie Flanagan, Michelle Giles, and Nigel Crawford. 2026. “ATAGI 2025 Annual Statement on Immunisation”. Communicable Diseases Intelligence 50 (May). https://doi.org/10.33321/cdi.2026.50.033.

Issue

Vol. 50 (2026)

Section

Recently published

Categories

License

Copyright (c) 2026 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.